Fred Alger Management’s Forte Biosciences FBRX Stock Holding History

Fred Alger Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.6M	Buy	1,439,697 +165,732	+13%	+$3.93M	0.1%	91
2026 Q1	$33M	Sell	1,273,965 -187,006	-13%	-$5.39M	0.14%	78
2025 Q4	$39.8M	Sell	1,460,971 -175,059	-11%	-$3.07M	0.16%	74
2025 Q3	$24.5M	Buy	1,636,030 +17,381	+1%	+$200K	0.1%	110
2025 Q2	$20.9M	Buy	1,618,649 +708,040	+78%	+$6.09M	0.09%	117
2025 Q1	$7.07M	Sell	910,609 -223,335	-20%	-$2.64M	0.04%	192
2024 Q4	$25.8M	Buy	1,133,944 +1,051,246	+1,271%	+$12.5M	0.12%	111
2024 Q3	$462K	Buy	82,698 +9,139	+12%	+$94K	﹤0.01%	381
2024 Q2	$988K	Hold	73,559	–	–	﹤0.01%	359
2024 Q1	$1.28M	Hold	73,559	–	–	0.01%	363
2023 Q4	$1.51M	Hold	73,559	–	–	0.01%	348
2023 Q3	$1.22M	Buy	+73,559	New	+$1.63M	0.01%	352
2021 Q3	–	Sell	-48,701	Closed	-$40.9M	–	531
2021 Q2	$40.9M	Buy	48,701 +26,417	+119%	+$23.8M	0.1%	172
2021 Q1	$19.1M	Buy	22,284 +2,963	+15%	+$2.43M	0.05%	206
2020 Q4	$17.6M	Buy	19,321 +688	+4%	+$647K	0.05%	202
2020 Q3	$22.6M	Sell	18,633 -10,333	-36%	-$6.85M	0.07%	159
2020 Q2	$10.6M	Buy	+28,966	New	+$12.9M	0.03%	184

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fred Alger Management's FBRX Position: Q2 2026 in Review

Fred Alger Management increased its Forte Biosciences (FBRX) stake by 13% in Q2 2026, buying an estimated $3.93M and bringing the position to 1,439,697 shares worth $30.6M. The position accounts for 0.1% of the portfolio, ranked #91.

Fred Alger Management first reported a position in FBRX in Q2 2020 and has held it in 17 quarters since. The position peaked at $40.9M in Q2 2021. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Fred Alger Management held 1,439,697 shares of Forte Biosciences worth $30.6M as of Q2 2026.
Fred Alger Management bought 165,732 Forte Biosciences shares in Q2 2026, an estimated $3.93M.
Forte Biosciences made up 0.1% of Fred Alger Management's portfolio in Q2 2026, its #91 holding.
Fred Alger Management first reported a position in Forte Biosciences in Q2 2020 and has held it in 17 quarters since.
Fred Alger Management's Forte Biosciences position peaked at $40.9M in Q2 2021.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.